Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?

Bibliographic Details
Main Author: David M. Reid
Format: Article
Language:English
Published: SAGE Publishing 2020-01-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X19895490
id doaj-4711a834c1574ee1b84a922a7f2e9669
record_format Article
spelling doaj-4711a834c1574ee1b84a922a7f2e96692021-07-14T11:33:36ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182020-01-011210.1177/1759720X19895490Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?David M. Reidhttps://doi.org/10.1177/1759720X19895490
collection DOAJ
language English
format Article
sources DOAJ
author David M. Reid
spellingShingle David M. Reid
Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
Therapeutic Advances in Musculoskeletal Disease
author_facet David M. Reid
author_sort David M. Reid
title Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
title_short Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
title_full Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
title_fullStr Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
title_full_unstemmed Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
title_sort balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
publisher SAGE Publishing
series Therapeutic Advances in Musculoskeletal Disease
issn 1759-7218
publishDate 2020-01-01
url https://doi.org/10.1177/1759720X19895490
work_keys_str_mv AT davidmreid balancingtherisksandbenefitsofbiologicdrugsinrheumaticdiseasethecaseforromosozumab
_version_ 1721303008061423616